1887

Abstract

Persistent infection with oncogenic human papillomavirus (HPV) is a prerequisite for cervical disease development, yet data regarding the host immune response to infection at the genotype level are quite limited. We created pseudoviruses bearing the major (L1) and minor (L2) capsid proteins and L1 virus-like particles representing the reference sequence and a consensus of 34 European sequences of HPV51. Despite the formation of similarly sized particles, motifs in the reference L1 and L2 genes had a profound impact on the immunogenicity, antigenicity and infectivity of these antigens. The antibody status of women exhibiting low-grade disease was similar between HPV16 and the consensus HPV51, but both demonstrated discrepancies between binding and neutralizing antibody responses. These data support the use of pseudoviruses as the preferred target antigen in studies of natural HPV infection and the need to consider variation in both the L1 and L2 proteins for the appropriate presentation of antibody epitopes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000121
2015-07-01
2020-01-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/7/1842.html?itemId=/content/journal/jgv/10.1099/vir.0.000121&mimeType=html&fmt=ahah

References

  1. Bernard H.-U. , Burk R.D. , Chen Z. , van Doorslaer K. , zur Hausen H. , de Villiers E.-M. . ( 2010;). Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70–79.[CrossRef]
    [Google Scholar]
  2. Bouvard V. , Baan R. , Straif K. , Grosse Y. , Secretan B. , El Ghissassi F. , Benbrahim-Tallaa L. , Guha N. , Freeman C. , other authors . ( 2009;). A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321–322.[CrossRef]
    [Google Scholar]
  3. Buck C.B. , Thompson C.D. . ( 2007;). Production of papillomavirus-based gene transfer vectors. . In Current Protocols in Molecular Biology Unit 26.1. Edited by Ausubel F. M. , Brent R. , Kingston R. E. , Moore D. D. , Seidman J. G. , Smith J. A. , Struhl K. . Hoboken, NJ: John Wiley & Sons;.
    [Google Scholar]
  4. Buck C.B. , Day P.M. , Trus B.L. . ( 2013;). The papillomavirus major capsid protein L1. Virology 445: 169–174.[CrossRef]
    [Google Scholar]
  5. Burk R.D. , Harari A. , Chen Z. . ( 2013;). Human papillomavirus genome variants. Virology 445: 232–243.[CrossRef]
    [Google Scholar]
  6. Carter J.J. , Koutsky L.A. , Hughes J.P. , Lee S.K. , Kuypers J. , Kiviat N. , Galloway D.A. . ( 2000;). Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911–1919.[CrossRef]
    [Google Scholar]
  7. Castellsagué X. , Naud P. , Chow S.N. , Wheeler C.M. , Germar M.J. , Lehtinen M. , Paavonen J. , Jaisamrarn U. , Garland S.M. , other authors . ( 2014;). Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 210: 517–534.[CrossRef]
    [Google Scholar]
  8. Chen H.S. , Conway M.J. , Christensen N.D. , Alam S. , Meyers C. . ( 2011;). Papillomavirus capsid proteins mutually impact structure. Virology 412: 378–383.[CrossRef]
    [Google Scholar]
  9. Culp T.D. , Spatz C.M. , Reed C.A. , Christensen N.D. . ( 2007;). Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361: 435–446.[CrossRef]
    [Google Scholar]
  10. de Sanjose S. , Quint W.G. , Alemany L. , Geraets D.T. , Klaustermeier J.E. , Lloveras B. , Tous S. , Felix A. , Bravo L.E. , other authors . ( 2010;). Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048–1056.[CrossRef]
    [Google Scholar]
  11. Dessy F.J. , Giannini S.L. , Bougelet C.A. , Kemp T.J. , David M.P. , Poncelet S.M. , Pinto L.A. , Wettendorff M.A. . ( 2008;). Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 4: 425–434.[CrossRef]
    [Google Scholar]
  12. Draper E. , Bissett S.L. , Howell-Jones R. , Edwards D. , Munslow G. , Soldan K. , Beddows S. . ( 2011;). Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29: 8585–8590.[CrossRef]
    [Google Scholar]
  13. Draper E. , Bissett S.L. , Howell-Jones R. , Waight P. , Soldan K. , Jit M. , Andrews N. , Miller E. , Beddows S. . ( 2013;). A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® Human Papillomavirus vaccines in 12–15 year old girls. PLoS ONE 8: e61825.[CrossRef]
    [Google Scholar]
  14. Duffy S. , Shackelton L.A. , Holmes E.C. . ( 2008;). Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 9: 267–276.[CrossRef]
    [Google Scholar]
  15. Guan P. , Howell-Jones R. , Li N. , Bruni L. , de Sanjosé S. , Franceschi S. , Clifford G.M. . ( 2012;). Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131: 2349–2359.[CrossRef]
    [Google Scholar]
  16. Howell-Jones R. , de Silva N. , Akpan M. , Oakeshott P. , Carder C. , Coupland L. , Sillis M. , Mallinson H. , Ellis V. , other authors . ( 2012;). Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 30: 3867–3875.[CrossRef]
    [Google Scholar]
  17. Huo Z. , Bissett S.L. , Giemza R. , Beddows S. , Oeser C. , Lewis D.J. . ( 2012;). Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS ONE 7: e33736.[CrossRef]
    [Google Scholar]
  18. Kondo K. , Ishii Y. , Mori S. , Shimabukuro S. , Yoshikawa H. , Kanda T. . ( 2009;). Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. Virology 394: 259–265.[CrossRef]
    [Google Scholar]
  19. Krajden M. , Cook D. , Yu A. , Chow R. , Su Q. , Mei W. , McNeil S. , Money D. , Dionne M. , other authors . ( 2014;). Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 32: 624–630.[CrossRef]
    [Google Scholar]
  20. Lehtinen M. , Dillner J. . ( 2013;). Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews. Clinical Oncology 10: 400–410.[CrossRef]
    [Google Scholar]
  21. Lin S.W. , Ghosh A. , Porras C. , Markt S.C. , Rodriguez A.C. , Schiffman M. , Wacholder S. , Kemp T.J. , Pinto L.A. , other authors . ( 2013;). HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS ONE 8: e53067.[CrossRef]
    [Google Scholar]
  22. Lungu O. , Crum C.P. , Silverstein S. . ( 1991;). Biologic properties and nucleotide sequence analysis of human papillomavirus type 51. J Virol 65: 4216–4225.
    [Google Scholar]
  23. Nakao S. , Mori S. , Kondo K. , Matsumoto K. , Yoshikawa H. , Kanda T. . ( 2012;). Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology 434: 110–117.[CrossRef]
    [Google Scholar]
  24. Ochi H. , Kondo K. , Matsumoto K. , Oki A. , Yasugi T. , Furuta R. , Hirai Y. , Yoshikawa H. , Kanda T. . ( 2008;). Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 15: 1536–1540.[CrossRef]
    [Google Scholar]
  25. Pastrana D.V. , Vass W.C. , Lowy D.R. , Schiller J.T. . ( 2001;). NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279: 361–369.[CrossRef]
    [Google Scholar]
  26. Pastrana D.V. , Buck C.B. , Pang Y.Y. , Thompson C.D. , Castle P.E. , FitzGerald P.C. , Krüger Kjaer S. , Lowy D.R. , Schiller J.T. . ( 2004;). Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205–216.[CrossRef]
    [Google Scholar]
  27. Piana A. , Sotgiu G. , Cocuzza C. , Musumeci R. , Marras V. , Pischedda S. , Deidda S. , Muresu E. , Castiglia P. . ( 2013;). High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy. PLoS ONE 8: e63395.[CrossRef]
    [Google Scholar]
  28. Raff A.B. , Woodham A.W. , Raff L.M. , Skeate J.G. , Yan L. , Da Silva D.M. , Schelhaas M. , Kast W.M. . ( 2013;). The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 87: 6062–6072.[CrossRef]
    [Google Scholar]
  29. Rhee S.Y. , Liu T.F. , Kiuchi M. , Zioni R. , Gifford R.J. , Holmes S.P. , Shafer R.W. . ( 2008;). Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5: 74.[CrossRef]
    [Google Scholar]
  30. Rositch A.F. , Koshiol J. , Hudgens M.G. , Razzaghi H. , Backes D.M. , Pimenta J.M. , Franco E.L. , Poole C. , Smith J.S. . ( 2013;). Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 133: 1271–1285.[CrossRef]
    [Google Scholar]
  31. Safaeian M. , Porras C. , Schiffman M. , Rodriguez A.C. , Wacholder S. , Gonzalez P. , Quint W. , van Doorn L.J. , Sherman M.E. , other authors . ( 2010;). Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102: 1653–1662.[CrossRef]
    [Google Scholar]
  32. Safaeian M. , Ghosh A. , Porras C. , Lin S.W. , Rodriguez A.C. , Schiffman M. , Wacholder S. , Kemp T. , Gonzalez P. , other authors . ( 2012;). Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 21: 1547–1554.[CrossRef]
    [Google Scholar]
  33. Schiffman M. , Castle P.E. , Jeronimo J. , Rodriguez A.C. , Wacholder S. . ( 2007;). Human papillomavirus and cervical cancer. Lancet 370: 890–907.[CrossRef]
    [Google Scholar]
  34. Schiller J.T. , Castellsagué X. , Garland S.M. . ( 2012;). A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30: (Suppl. 5), F123–F138.[CrossRef]
    [Google Scholar]
  35. Seitz H. , Schmitt M. , Bohmer G. , Kopp-Schneider A. , Muller M. . ( 2012;). Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int J Cancer 132: E139–E148.[CrossRef]
    [Google Scholar]
  36. Syrjänen S. , Waterboer T. , Sarkola M. , Michael K. , Rintala M. , Syrjänen K. , Grenman S. , Pawlita M. . ( 2009;). Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 90: 1515–1526.[CrossRef]
    [Google Scholar]
  37. Tamura K. , Stecher G. , Peterson D. , Filipski A. , Kumar S. . ( 2013;). mega6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30: 2725–2729.[CrossRef]
    [Google Scholar]
  38. Wang J.W. , Roden R.B. . ( 2013;). L2, the minor capsid protein of papillomavirus. Virology 445: 175–186.[CrossRef]
    [Google Scholar]
  39. Wilson L.E. , Pawlita M. , Castle P.E. , Waterboer T. , Sahasrabuddhe V. , Gravitt P.E. , Schiffman M. , Wentzensen N. . ( 2013;). Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int J Cancer 133: 2172–2181.[CrossRef]
    [Google Scholar]
  40. Wilson L. , Pawlita M. , Castle P.E. , Waterboer T. , Sahasrabuddhe V. , Gravitt P.E. , Schiffman M. , Wentzensen N. . ( 2014;). Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 210: 448–455.[CrossRef]
    [Google Scholar]
  41. Xi L.F. , Carter J.J. , Galloway D.A. , Kuypers J. , Hughes J.P. , Lee S.K. , Adam D.E. , Kiviat N.B. , Koutsky L.A. . ( 2002;). Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 11: 343–351.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000121
Loading
/content/journal/jgv/10.1099/vir.0.000121
Loading

Data & Media loading...

Supplements

Supplementary Data



PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error